Member Info for ForFXSake

No, just a realist

The problem is we have a part time board with other fish to fry. They only seem interested in boosting sentiment when money is about to run out. When the coffers are full again they seem to sit back. It's like they treat Nuformix more as a hobby than the potential blockbuster they tell us it is.

Approaching 4 months now since raise and FDA ODD granted. Incredible that there is still no timeline or development plan and no visibility on 'partners'. Nothing at all about due dilligence tests, which should have been ready to go as soon as the news dropped.

How do you know?

We've been waiting 6 years already

Are you still wrong OSD?

Be careful though, you might get labelled as anti-P&D, de-ramping, trolling scum 🤣

Where are the partners (and the due dilligence test results)?

Are you a lapdog, Littlened?

I've always known that.

I'm sure they all do too now.

I've always known that.

I'm sure they all do too now.

Really?

How reassuring those words must be for all those who listen to you.

That's an interesting statement from someone who holds 25m shares!

Have you accepted that outcome?

Ask why they are still accruing salaries, for one?

You didn't answer my question about why they chose to pursue ODD for 3 years instead of phase 1, if they knew the chances of getting a deal were minimal for pre-clinical?

Wouldn't it better if the board changed and actually did something to add value the share price? We've had nothing but decline since 2020.

You say that shareholders should change accordingly but why should we? Surely you must agree that change is well overdue with the boaed with regards to the constant failure to deliver value?

When I invested there was:

* NXP001 flying high and already owed £2m royalty from Chinese firm

* NXP002 engaged with Kissei on verge of £200m plus deal due to be agreed imminently

* £50m Ebers deal for canabinoids work

* Fledgling NXP004 in the pipeline

So yeah, I did think there was a likelihood of something coming off. I though it would be pretty remote for all of that to disappear and the board disintegrate.

It seemed a little bit more hopeful back then. Wouldn't you agree?

"Or maybe look at how many outlicensing deals for IPF therapies have been concluded in the pre-clinical stage, you can probably count them on one hand."

So that begs the question why Gooding has wasted 3 years focussing on fruitless ODD submissions when he could have used all that money to get us to phase 1 instead?

Didn't they release some kind of 3rd party analysis/prospectus back in 2022 that said we were about a year from entering phase 1? What happened to that?

Then, in 2023 it was all about ODD being critical to a deal.

Now the excuses appear to be that it's almost impossible to get a deal in pre-clinical!

Does this board have any real clues about how to move NXP002 forward or are they just holding out for a minnow with nothing but peanuts to offer?

Yes Littlened. None of them adding any value. I think the The 'Total Voting Rights' one was the one I founf most interesting.

Where are the partners?

We know why you're here Littlened...cos you're still locked in!

Not very good at this P&D lark, are you?

🤣

WhoWroteThis,

I have told you multiple times that I don't have much faith in what the board says. That is not unreasonable or nonsense given everything I have witnessed since 2020.

Formal RNS updates are notorious for painting in a positive slant and companies (not just Nuformix) will often use clever/careful wording to make things sound rosier than they actually are. It is therefore their actions that count, not their words.

In all this time, to this day and with all this supposed potential, the price has gone nowhere but down. That is the result of their actions.

Yes, they have managed to gain ODD grants but it took a hell of a long time. If I remember rightly, the first utterings about the importance of going for EMA ODD to get a deal started in about Feb 2023. Look back to the LSE posts of that time for a fuller picture. There was alot of speculation back then about when submission would occur or if it already had. I think it all emerged from Telegram conversation in which Gooding was allegedly involved rather than RNS but it was basically the start of the eternal fruitless partner discussions era. People thought submission must have been imminent and a response would be in around 90 to 120 days or so from that point. So we should maybe have known sometime in H2 2023? It took until January 2025 before they even submitted the application (see RNS)....almost 2 years!!! What were they doing in all that time?

It was all supposed to be about getting a deal. They say we are still talking but we still don't see any signs of them. That's why I keep banging the repetitive drum: "Where are the partners"?

This may be just diatribe to you but at the end of the day true investors stick around and want a return. It is way past time this board delivered and there is still no tangible evidence of them doing it...just words.

WRT, you must have quite an elevated opinion of yourself if you think that, just because you spend all day searching through masses of RNS' to try and a find quotes to justify your opinion, I am going spend all night reading them. I've read them before. I think most of them are full of guff.

You continually call me childish yet you seem incapable of civil discourse, having to resort to childish name calling and insults when people won't see it your way. Alas, your hurty words have no effect on me...sticks n stones and all that.

As you seem to like RNS', here's a quote from the unaudited interrim report from 22nd May 2023:

'Dr Dan Gooding, Executive Director of Nuformix, said: "Our interim report demonstrates the Company is continuing to generate value-adding data for its lead programmes whilst further optimising its operational costs. For NXP002, our pre-clinical strategy has delivered consistently positive results that allow us to tell a complete pre-clinical story to potential licensing partners for the first time and demonstrate that inhaled treatment of IPF via NXP002 is a viable concept. Our near-term goals focus on our NXP002 programme, as we continue to generate robust data to support our out-licensing objectives, all achievable using existing funds thanks to our lean operational model which will continue to operate.'

Interesting words there:

"results that allow us to tell a complete pre-clinical story to potential licensing partners" - so why no takers yet, why more due dilligence? I thought the picture was complete.

"as we continue to generate robust data to support our out-licensing objectives, all achievable using existing funds" - existing funds? Exactly how many fundraisers have there been since?

Was that really factual?

Now stop getting your knickers in a twist and go and have a nice lie down.

WRT has now taken comical Ali's place in blurging vast amounts of garbage. Life is too short.

The facts are easy to comprehend:

3 years since 'partnership' discussions commenced - still no sign of a partner

Over a year since EMA ODD and 3 months since FDA ODD granted - still no sign of a partner

No partners, no test results, no deadlines. This board appears to be just winging it from fund raise to fund raise without any real endgame plan that I can see.

Do you have any hard evidence that they are progressing? By hard, I mean other yhan what you been told by the board...which is worthless until proven as they have been saying the same thing since early 2023. That doesn't make it factual as the 'fact' is very open to interpretation.

I haven't trusted anything the board has said since mid 2020, despite it's revolving door.